TEVA Teva Pharmaceutical Industries
- 13.810
- +0.560+4.23%
- 13.710
- -0.100-0.72%
Teva Pharmaceutical Industries News
Express News | NYSE Order Imbalance 120851.0 Shares on Sell Side
AbbVie Stock Slides 6% Amid Concerns About Falling Humira Sales
Cigna to Offer Humira Rivals With $0 Copay at Specialty Pharmacy
Express News | NYSE Order Imbalance 133734.0 Shares on Sell Side
Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of Its Petition in HETLIOZ ANDA Litigation
Vanda Pharmaceuticals Appeal for Patents on Sleep Drug Declined by US Supreme Court
Vanda Pharmaceuticals' (VNDA) appeal to revive patent protections for its Hetlioz sleep-disorder medication was declined by the US Supreme Court, upholding a decision in favor of generic drugmakers Te
Express News | NYSE Order Imbalance 57025.0 Shares on Sell Side
US Supreme Court Reportedly Declines to Hear Vanda Patent Case
U.S. Supreme Court Rejects Vanda Pharmaceuticals Case Over Sleep-drug Patents
Peptide Therapeutics Analysis Report 2024 - Global Forecast to 2030 Featuring Eli Lilly and Co, Pfizer, Amgen, Takeda, AstraZeneca, Teva, Sanofi, F. Hoffmann-La Roche, Novartis, Novo Nordisk
Express News | NYSE Order Imbalance 82586.0 Shares on Sell Side 82586.0 Shares on Sell Side
Alvotech, Teva Signs Deal to Expand Access for Humira Biosimilar in U.S.
Alvotech Inks Long-Term Agreement With A Strategic Partner To Further Enhance Access To Adalimumab-ryvk In US Market
"This new partnership agreement supports our financial guidance and reflects Alvotech's strong commitment to increasing patient access to more affordable healthcare," said Robert Wessman, Chairman and
Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris
Express News | Teva Pharmaceuticals Decided That Canada Will No Longer Be Included As Part Of Teva's North America Segment As Of Jan. 1, 2024
Express News | NYSE Order Imbalance 90302.0 Shares on Buy Side 90302.0 Shares on Buy Side
3 Generic Drug Stocks to Watch Amid Challenging Market Prospects
CVS Favors Humira Copycats Hurting AbbVie's Market Share: Evercore
Alvotech, Teva Get FDA Approval for Stelara Biosimilar Psoriasis Treatment
Alvotech and Teva Pharmaceuticals said the Food and Drug Administration approved the Selarsdi injection for subcutaneous use as a biosimilar to Stelara for the treatment of psoriasis.
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI (Ustekinumab-aekn), Biosimilar to Stelara (Ustekinumab)
Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara.
Analysis
Price Target
No Data
